Enhanced production of lovastatin by Omphalotus olearius (DC.) Singer in solid state fermentation

Atlı, Burcu; Yamaç, Mustafa; Yıldız, Zeki; Isikhuemnen, Omoanghe S.

doi:10.1016/j.riam.2014.06.008

Cited by 4 publications

(4 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…showed that a maximum lovastatin titer of 139.47 mg g −1 was achieved by the fermentation of 5 g of barley, 1–2 mm particle diam, at 28°C. [ 47 ] Barley, long‐grain rice, and sago starch have also shown promise in statin production, with maximum titer of lovastatin reaching 193.7, 190.2, and 180.9 mg g −1 , respectively, by M. purpureus MTCC 369. [ 48 ] Suraiya et al.…”

Section: Non‐genetic Strategies Improving Statins Productionmentioning

confidence: 99%

“…Wheat bran has been identified as a suitable substrate, yielding 16.65 mg g −1 of lovastatin in aerated stirred beds after 6 days of fermentation by A. flavipes BICC 5174. [46] Atlı et al showed that a maximum lovastatin titer of 139.47 mg g −1 was achieved by the fermentation of 5 g of barley, 1-2 mm particle diam, at 28 • C. [47] Barley, long-grain rice, and sago starch have also shown promise in statin production, with maximum titer of lovastatin reaching 193.7, 190.2, and 180.9 mg g −1 , respectively, by M. purpureus MTCC 369. [48] Suraiya et al showed that glucose had the greatest influence on the production of lovastatin, with an average titer of 13.98 mg gds −1 (milligram per gram of dry substrate) achieved using M.…”

Section: The Effects Of Medium Compositionmentioning

confidence: 99%

See 1 more Smart Citation

Improving statins production: From non‐genetic strategies to genetic strategies

Fan

Tang

Yang

et al. 2023

Biotechnology Journal

View full text Add to dashboard Cite

Statins are lipid‐lowering drugs that selectively inhibit 3‐hydroxy‐3‐methylglutaryl coenzyme A (HMG‐CoA) reductase, effectively reducing cholesterol synthesis. With improved nutritional conditions, the demand for statins is increasing in the global market. The use of microbial cell factories for statin biosynthesis has become advantageous due to the rapid advancements in biotechnology. These approaches offer simple operation and easy separation of products. This review provides an overview the strategies for statins production via microbial cell factories, including both traditional fermentation culture (non‐genetic) and modern synthetic biology manufacture (genetic). Firstly, the complex fermentation parameters and process control technology on submerged fermentation (SmF) and solid‐state fermentation (SSF) are introduced in detail. The potential use of recoverable agricultural wastes/(biomass) as a fermentation substrate in SSF for statin production is emphasized. Additionally, metabolic engineering strategies for constructing robust engineering strains and directed evolution are also discussed. The review highlights the potential and challenges of using microbial cell factories for statin production, and aims to promote greener production modes for statins.This article is protected by copyright. All rights reserved

show abstract

Section: Non‐genetic Strategies Improving Statins Productionmentioning

confidence: 99%

Section: The Effects Of Medium Compositionmentioning

confidence: 99%

Improving statins production: From non‐genetic strategies to genetic strategies

Fan

Tang

Yang

et al. 2023

Biotechnology Journal

View full text Add to dashboard Cite

show abstract

“…flavipes BICC 5174. Atlı et al (Atlı, Yamaç et al 2015) showed that a maximum lovastatin titer of 139.47 mg/g was achieved by the fermentation of 5 g of barley, 1-2 mm particle diam, at 28 °C. Subhagar et al (Subhagar, Aravindan et al 2009) showed barley, long grain rice and sago starch were the suitable substrates producing.…”

Section: Mediummentioning

confidence: 99%

Strategies for the statins production in microbial cell factory：present and future

Fan

Tang

Zhao

et al. 2023

Preprint

View full text Add to dashboard Cite

Statins as a lipid-lowering drug can selectively inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase and decrease cholesterol synthesis effectively. With the improvement of nutritional conditions, the demand for statins is increasing in global market. Due to the rapid development of modern biotechnologies, the biosynthesis of stains by microbial cell factory appears great advantages. It has the advantages of simple operation and easy separation of products. This review summarized the strategies on statins production via microbial cell factory, including both traditional fermentation culture and modern synthetic biology manufacture. Firstly, the complex fermentation parameters and process control technology on submerged fermentation (SmF) and solid-state fermentation (SSF) were introduced in detail. Especially, the possibility of recoverable agricultural wastes/(Biomass) as fermentation substrate on solid-state fermentation to produce statins was emphasized. Besides, metabolic engineering strategies to construct robust engineering strains and strains evolution were also discussed. The review highlights the potential and challenge of microbial cell factory to yield the statins. Thus, it will facilitate the production of statins in more green production mode.

show abstract

“…The antioxidant activity of -cryptoxanthin was evaluated in non-alcoholic fatty liver disease by several authors [44][45][46][47]. That's studies shown an important reduction in lipogenesis -oxidation [48][49][50], and reduction in lipid peroxidation [48,51] showing a protective response in steatohepatitis and cirrhosis. In addition that compound shown an influence in macrophage polarization, increasing the polarization for macrophages M2, and reducing the polarization for macrophages M1 [9].…”

Section: Crude Extractmentioning

confidence: 99%

Compounds isolated from Bixa orellana: evidence-based advances to treat infectious diseases

Neto

Coutinho

Rezende

et al. 2020

Rev. Colomb. Cienc. Quím. Farm.

View full text Add to dashboard Cite

Bixa orellana L. is a native plant from Brazil, but it is also present in other tropical countries such as Peru, Colombia, Ecuador, Mexico, Indonesia, India and East Africa. It is popularly known as Urucum in Brazil. This review shows the potential of bioactive compounds derived from B. orellana to treat infectious diseases due their antimicrobial and antioxidant properties. This plant is also related as an anti-inflammatory agent for treatment of pulmonary diseases, or even as eye drops for redness. Its leaves are used for treatment of snakebite, diarrhea, gonorrhea, hepatitis, gastritis, diuretic, antipyretic, and for skin disease. This popular knowledge has encouraged the identification of bioactive compounds in this plant. Compounds as β-cryptoxanthin, geranylgeraniol, lutein, procyanidin B2, procyanidin B3, ellagitannin isomer and ellagic acid deoxyhexose have been described. These compounds inhibited pathogenic microorganisms such as bacteria, fungi, protozoan and viruses. In addition, some compounds with anti-inflammatory and antioxidant activities were also described. In this sense, B. orellana is a promising source of compounds that could be applied in antimicrobial therapy. This review work may help in the understanding and incentive of new research for antimicrobial discoveries using different B. orellana compounds.

show abstract

Enhanced production of lovastatin by Omphalotus olearius (DC.) Singer in solid state fermentation

Cited by 4 publications

References 17 publications

Improving statins production: From non‐genetic strategies to genetic strategies

Improving statins production: From non‐genetic strategies to genetic strategies

Strategies for the statins production in microbial cell factory：present and future

Compounds isolated from Bixa orellana: evidence-based advances to treat infectious diseases

Contact Info

Product

Resources

About